Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis.
- Author(s): Reddy, Vidhatha
- Yang, Eric J
- Myers, Bridget
- Liao, Wilson
- et al.
Published Web Locationhttps://doi.org/10.2147/jir.s215196
Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.